FLT4 and breast carcinoma: Decreases levels of vascular endothelial growth factor (VEGF)-C, VEGF receptor-3, nuclear factor kappa β, phospho-Akt, and phospho-PI3K in HLEC. Decreases micro-lymphatic vascular density in an MDA-MB-231 nude mouse model of breast cancer.